{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:09:39Z","timestamp":1784196579668,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Centre for Pharmaceutical Regulatory Sciences at the University of Macau","award":["CPRS-0005"],"award-info":[{"award-number":["CPRS-0005"]}]},{"DOI":"10.13039\/501100004733","name":"Universidade de Macau","doi-asserted-by":"publisher","award":["MYRG-GRG2023-00059-ICMS"],"award-info":[{"award-number":["MYRG-GRG2023-00059-ICMS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Development Fund, Macau SAR","award":["0014\/2023\/AKP"],"award-info":[{"award-number":["0014\/2023\/AKP"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01534-7","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:53:43Z","timestamp":1784195623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World"],"prefix":"10.1007","volume":"57","author":[{"given":"Menghuan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Oi Lam","family":"Ung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9441-106X","authenticated-orcid":false,"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"6","key":"1534_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2020","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2020;77(6):1598\u2013606.","journal-title":"J Hepatol"},{"issue":"2","key":"1534_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3350\/cmh.2023.0070","volume":"29","author":"JH Oh","year":"2023","unstructured":"Oh JH, Jun DW. The latest global burden of liver cancer: a past and present threat. Clin Mol Hepatol. 2023;29(2):355\u20137.","journal-title":"Clin Mol Hepatol"},{"key":"1534_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1534_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"20","key":"1534_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"4","key":"1534_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"10126","key":"1534_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"8","key":"1534_CR8","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid"},{"issue":"8","key":"1534_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","volume":"23","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, Rimassa L, Cheng A-L, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995\u20131008.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1534_CR10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1534_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.14715\/cmb\/2022.68.11.10","volume":"68","author":"S Wen","year":"2022","unstructured":"Wen S, Zeng J, Zhong L, Ye J, Lai X. The efficacy and adverse effects of nivolumab and lenvatinib in the treatment of advanced hepatocellular carcinoma. Cell Mol Biol. 2022;68(11):53\u20137.","journal-title":"Cell Mol Biol"},{"key":"1534_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109223","volume":"112","author":"T-R Peng","year":"2022","unstructured":"Peng T-R, Wu CC, Chang S-Y, Chen Y-C, Wu T-W, Hsu C-S. Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma. Int Immunopharmacol. 2022;112:109223.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1534_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s10637-022-01248-0","volume":"40","author":"W-C Wu","year":"2022","unstructured":"Wu W-C, Lin T-Y, Chen MH, Hung YP, Liu C-A, Lee RC, et al. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs. 2022;40(4):789\u201397.","journal-title":"Invest New Drugs"},{"issue":"16","key":"1534_CR14","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.3390\/jcm11164874","volume":"11","author":"S-W Lee","year":"2022","unstructured":"Lee S-W, Yang S-S, Lien H-C, Peng Y-C, Tung C-F, Lee T-Y. The combining of tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for advanced stage hepatocellular carcinoma. J Clin Med. 2022;11(16):4874.","journal-title":"J Clin Med"},{"key":"1534_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","volume":"152","author":"T Mikami","year":"2021","unstructured":"Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D, et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021;152:135\u201344.","journal-title":"J Neurooncol"},{"issue":"12","key":"1534_CR16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"J-E Salem","year":"2018","unstructured":"Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: a pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"key":"1534_CR17","volume-title":"Medical Dictionary for Regulatory Activities","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2024","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Medical Dictionary for Regulatory Activities. Geneva: ICH; 2024."},{"issue":"7","key":"1534_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"1","key":"1534_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12885-023-11112-w","volume":"23","author":"X Gao","year":"2023","unstructured":"Gao X, Zhao R, Ma H, Zuo S. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis. BMC Cancer. 2023;23(1):635.","journal-title":"BMC Cancer"},{"key":"1534_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221080298","volume":"14","author":"T de Castro","year":"2022","unstructured":"de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022;14:17588359221080298.","journal-title":"Ther Adv Med Oncol"},{"issue":"19","key":"1534_CR21","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.2217\/fon-2020-1222","volume":"17","author":"GP Sonpavde","year":"2021","unstructured":"Sonpavde GP, Grivas P, Lin Y, Hennessy D, Hunt JD. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. Future Oncol. 2021;17(19):2545\u201358.","journal-title":"Future Oncol"},{"key":"1534_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang J, Yan J, Liu B. Targeting VEGF\/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978.","journal-title":"Front Immunol"},{"issue":"26","key":"1534_CR23","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960\u201370.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1534_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437\u201348.","journal-title":"N Engl J Med"},{"issue":"8","key":"1534_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1470-2045(20)30271-0","volume":"21","author":"A Kawazoe","year":"2020","unstructured":"Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(8):1057\u201365.","journal-title":"Lancet Oncol"},{"key":"1534_CR26","unstructured":"Flynn JP, Gerriets V, Pembrolizumab. StatPearls [Internet]. 2024."},{"issue":"15_suppl","key":"1534_CR27","doi-asserted-by":"publisher","first-page":"e15000","DOI":"10.1200\/JCO.2020.38.15_suppl.e15000","volume":"38","author":"TZ Kewan","year":"2020","unstructured":"Kewan TZ, Ahmed R, Alqaisi S, Covut F, Flores M, Babar A, et al. Risk of bleeding and significant thrombocytopenia in cancer patients treated with immune checkpoint inhibitors. J Clin Oncol. 2020;38(15_suppl):e15000.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1534_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang Y-N, Wang K-T, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2020;1874(1):188391.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"10","key":"1534_CR29","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/eurjpc\/zwac033","volume":"29","author":"M Lettino","year":"2022","unstructured":"Lettino M, Mascherbauer J, Nordaby M, Ziegler A, Collet JP, Derumeaux G, et al. Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology-Cardiovascular Round Table. Eur J Prev Cardiol. 2022;29(10):1412\u201324.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"1534_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s41999-020-00355-6","volume":"11","author":"G Fagundes Belchior","year":"2020","unstructured":"Fagundes Belchior G, Kirk B, Pereira da Silva EA, Duque G. Osteosarcopenia: beyond age-related muscle and bone loss. Eur Geriatr Med. 2020;11(5):715\u201324.","journal-title":"Eur Geriatr Med"},{"issue":"9","key":"1534_CR31","doi-asserted-by":"publisher","first-page":"sfae235","DOI":"10.1093\/ckj\/sfae235","volume":"17","author":"Y Tang","year":"2024","unstructured":"Tang Y, Jiang J, Zhao Y, Du D. Aging and chronic kidney disease: epidemiology, therapy, management and the role of immunity. Clin Kidney J. 2024;17(9):sfae235. https:\/\/doi.org\/10.1093\/ckj\/sfae235","journal-title":"Clin Kidney J"},{"key":"1534_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2021.11.024","volume":"162","author":"N Lyu","year":"2022","unstructured":"Lyu N, Yi J-Z, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer. 2022;162:76\u201398.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1534_CR33","first-page":"19","volume":"6","author":"JL Rodgers","year":"2019","unstructured":"Rodgers JL, Jones J, Bolleddu SI, Vanthenapalli S, Rodgers LE, Shah K, et al. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis. 2019;6(2):19.","journal-title":"J Cardiovasc Dev Dis"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01534-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:53:46Z","timestamp":1784195626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01534-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01534-7","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"155"}}